Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash Flows From Operating Activities    
Net income $ 1,918 $ 4,821
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 307 205
Interest accretion expense 34
Amortization of deferred financing fees 42
Stock-based compensation 31 218
Bad debt expense reversal (100)
Credit loss expense 26
Asset impairment - lab supplies 198
Change in fair value of note payable 87 445
Amortization on operating lease right of use asset 293 332
Other changes in operating assets and liabilities:    
Accounts receivable 2,578 (2,241)
Other current assets (213) 237
Accounts payable (417) 137
Accrued salaries and bonus (777) (320)
Other accrued expenses (385) (236)
Operating lease liabilities (283) (355)
Other long-term liabilities 314 259
Net cash provided by operating activities 3,693 3,462
Cash Flows From Investing Activity    
Purchase of property and equipment (318) (747)
Net cash used in investing activities (318) (747)
Cash Flows From Financing Activities    
Payments made on note payable (3,400) (4,100)
Series C conversion costs (13)
Net cash used in financing activities (3,413) (4,100)
Net decrease in cash and cash equivalents (38) (1,385)
Cash and cash equivalents from continuing operations– beginning 1,461 3,498
Cash and cash equivalents from discontinued operations– beginning
Cash and cash equivalents – beginning 1,461 3,498
Cash and cash equivalents from continuing operations– ending 1,423 2,113
Cash and cash equivalents from discontinued operations– ending
Cash and cash equivalents – ending $ 1,423 $ 2,113